Allergan 4Q13 4Q Revenues: $1.7 bilion (+14%) 4Q Earnings: $312 million (-4%) FY Revenues: $6.3 billion (+12%) FY Earnings: $989 million (-10%) Comments: Specialty Pharmaceuticals revenues were up 14% to $1.4 billion in 4Q, with Botox contributing $526 million (+11%), and eye care pharmaceuticals adding $782 million (+11%). For FY13, Botox revenues were up 12% to $2.0 billion while eye care pharmaceuticals were up 7% to $2.9 billion....